Sepsis 2013: Hot off the Press

Kaplow, 2014

1

Introduction

• > 750,000 cases/year• > 500 - 1000 Americans die daily• Overall mortality rate 28-50%• Estimated cost of $5-10B/year

2

SIRS Sepsis Severe Septic MODS Sepsis Shock

Sepsis: A Clinical Continuum

3

4

5

Diagnostic Criteria for Sepsis

Physical Findings• Fever (> 38.3 ｰ C)

• Hypothermia (core < 36° C)

• Heart rate > 90/min

• Tachypnea

• Altered mental status

• Significant edema or positive fluid balance (> 20 mL/kg over 24 hr)

• Hemodynamic variables

• Hypotension (SBP < 90, MAP < 70, or SBP decrease > 40 mm Hg

Lab Findings

• Hyperglycemia (glucose > 140 mg/dL) in the absence of diabetes

• Leukocytosis (WBC count > 12,000)

• Leukopenia (WBC count < 4000)

• Normal WBC count with > 10% bands

• Elevated CRP

• Elevated procalcitonin level

6

Diagnostic Criteria for Sepsis (cont’d)

Organ Dysfunction Variables

• Hypoxemia (PaO2/FiO2 < 300)

• Acute oliguria (urine output < 0.5 mL/kg/hr for at least 2 hrs despite adequate fluid resuscitation)

• Creatinine increase > 0.5 mg/dL

• Coagulation abnormalities (INR > 1.5 or aPTT > 60 s)

• Ileus (absent bowel sounds)

• Thrombocytopenia (PLT < 100,000)

• Total bilirubin > 4 mg/dL)

Tissue Perfusion Variables

• Hyperlactatemia (> 1 mmol/L)

• Decreased capillary refill or mottling

7

Diagnostic Criteria for Severe Sepsis

• Sepsis-induced hypotension

• Lactate above ULN

• Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation

• Acute lung injury with:– PaO2/FiO2 < 250 without pneumonia

– PaO2/FiO2 < 200 with pneumonia

• Creatinine > 2.0 mg/dL

• Bilirubin > 2 mg/dL

• Platelet count < 100,000 μL

• Coagulopathy (INR > 1.5)

8

9

CNS Acute change in MS (confusion, agitation, lethargy) or GCS < 15 (previously normal or decreased by 1)

Pulmonary Unexplained hypoxemia with suspected sepsis

(P/F < 200), bilateral infiltrates with PAOP < 18

Renal Oliguria, inc. serum creatinine from normal with urine Na < 40 mmol/L, rise in serum creatinine by 2 mg/dL in presence of preexisting renal insufficiency

Hepatobiliary Inc. LFTs to 2x normal, serum bilirubin > 2 mg/dL

GI Paralytic ileus, GI bleeding

Coagulation Confirmatory test for DIC (FDP > 1.4 or D-dimers > 2, thrombocytopenia or fall in platelets by 25%, inc. PT, PTT, clinical evidence of bleeding

10

11

12

Cytokines

• Mediators of inflammation• Critical parts of the immune system• Increased levels during shock• TNF and IL-1: widespread effects released early in systemic inflammatory response

13

Systems and Mediators AffectedIn Septic Shock

Complement System Coagulation CascadeFibrinolytic System CatecholaminesCachetin (TNF) HistamineIL-1 Circulating MDFPAF MacrophageLeukotrienes O2 free radicalsProstaglandins Inflammatory proteinsThromboxane A2

14

Vascular Endothelium

Regulates:• Blood vessel tone• Vascular permeability• Coagulation• WBC and platelet activity• Phagocytosis of bacteria

15

16

17

18

Signs and Symptoms of Sepsis

General

• Fever• Chills• Fatigue• Malaise• Rigors• Warm, pink peripheries

19

Signs and Symptoms of Sepsis

CNS

• Confusion• Anxiety• Disorientation• Apprehension • Agitation• Obtunded or comatose

20

Signs and Symptoms of Sepsis

Cardiovascular

• Tachycardia• Increased pulse pressure• Hypotension• Cardiac output normal or increased• Normal capillary refill

21

Signs and Symptoms of Sepsis

Pulmonary

• Hyperventilation• Respiratory alkalosis• SOB• Tachypnea

22

Signs and Symptoms of Sepsis

GI/GU

• Nausea and vomiting• Decreased albumin• Jaundice• Oliguria

23

Signs and Symptoms of Sepsis

Hematologic

• WBC increased or decreased• Increased INR, aPTT• DIC• Decreased platelets

24

Signs and Symptoms of Sepsis

Metabolic • Increased base deficit• Increased lactate• Increased glucose

25

Surviving Sepsis Campaign Bundles

To be completed within 3 hours:• Measure lactate level

• Obtain blood cultures prior to administration of antibiotics

• Administer broad spectrum antibiotics

• Administer 30 ml/kg crystalloid for hypotension or lactate ≥4mmol/L

*Targets are CVP of ≥8 mm Hg; ScvO2 of ≥70%, and normalization of lactate.

To be completed within 6 hours:•Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a MAP ≥65 mm Hg•In the event of persistent hypotension despite volume resuscitation or initial lactate ≥4 mmol/L (36 mg/dL):--Measure CVP* and central venous oxygen saturation (ScvO2)*Remeasure lactate if initial lactate was elevated*

26

Management of Septic Shock

• ABCs, antimicrobials• Volume resuscitation• Vasopressor therapy• Inotropic support• ? Steroids• ? Bicarbonate therapy

• Blood products• Glucose control• Supportive therapies• Ventilator support• Sedation, analgesia, and

neuromuscular blockade

27

Recommendations: Initial Resuscitation and Infection Issues: Initial Resuscitation

1. Resuscitation of patients with sepsis-induced tissue hypoperfusion (defined as hypotension persisting after initial fluid challenge or blood lactate ≥ 4 mmol/L). Goals during the first 6 hours of resuscitation:

a) Central venous pressure 8–12 mm Hg

b) MAP ≥ 65 mm Hg

c) U/O ≥ 0.5 mL/kg/hr

d) Central venous (superior vena cava) or mixed venous oxygen saturation 70% or 65%, respectively

2. In patients with elevated lactate levels targeting resuscitation to normalize lactate 28

Recommendations: Initial Resuscitation and Infection Issues: Antimicrobial Therapy

1. Administration of effective intravenous antimicrobials within the first hour of recognition of septic shock and severe sepsis.

2a. Initial empiric anti-infective therapy of one or more drugs that have activity against all likely pathogens and that penetrate tissues presumed to be the source of sepsis.

2b. Antimicrobial regimen should be reassessed daily for potential de-escalation.

29

Recommendations: Initial Resuscitation and Infection Issues: Antimicrobial Therapy

(cont’d)3. Use of low procalcitonin levels or biomarkers to assist in the discontinuation of empiric antibiotics in patients who initially appeared septic, but have no evidence of infection.

4a. Combination empirical therapy for neutropenic patients with severe sepsis and those with difficult-to-treat, MDR bacteria such as Acinetobacter and Pseudomonas.

4b. Empiric combination therapy should not be administered for more than 3–5 days. De-escalation to the most appropriate single therapy should be performed as soon as the susceptibility profile is known.

 30

Recommendations: Initial Resuscitation and Infection Issues: Antimicrobial

Therapy (cont’d)5. Duration of therapy typically 7–10 days; longer courses may

be appropriate in patients who have a slow clinical response, undrainable foci of infection, S. aureus; some fungal and viral infections or immunologic deficiencies, including neutropenia.

6. Antiviral therapy initiated as early as possible in patients with severe sepsis or septic shock of viral origin.

7. Antimicrobial agents should not be used in patients with severe inflammatory states determined to be of noninfectious cause.

31

32

33

Volume Resuscitation

• Crystalloids for initial choice• No hydroxyethyl starches• Albumin in severe sepsis and septic shock if substantial amounts of crystalloids are required. • Titrate to clinical endpoints

urine output lactic acid decreased HR increased B/P improved mental status

34

35

Vasopressor Therapy

• Norepinephrine (NE)• Epinephrine (added or substitute for NE)• Vasopressin 0.03 units/min (may be added to supplement or decrease NE). Higher doses should be reserved for salvage therapy. Low dose vasopressin not recommended as a single agent.• Dopamine (only in highly selected patients) No renal dopamine.• Phenylephrine (not recommended except in serious arrhythmias, high CO and persistent hypotension, or salvage therapy).

(Titrate to MAP 65 mm Hg. All patients on pressors should have an arterial catheter placed ASAP.)

36

37

38

39

Inotropic Therapy

• Optimization of filling pressures• Tachyarrhythmias – undesirable s/e• Usually need in conjunction with vasopressor• Not used to increase CI to supra-normal levels

Dobutamine trial up to 20 mcg/kg/min if myocardial dysfunction is suspected by elevated PAOP

40

Corticosteroid Therapy

• Do not use for sepsis– only septic shock.• Do not use if fluids and vasopressors keep MAP > 65.• If MAP not maintained, administer hydrocortisone 200 mg/day• Do not use ACTH stimulation test.• Don’t forget to taper.

41

Bicarbonate Therapy

• Not routinely indicated• Doesn’t improve effectiveness of vasoactive agents• Doesn’t correct hemodynamics or decrease pressor requirements despite correction of acidemia• No longer given empirically.• May be used for pH < 7.15.

42

Blood Product Administration

• Target hemoglobin 7-9 g/dL in adults.

• May be administered once hypoperfusion resolved, or• May be administered immediately if:

• Myocardial ischemia

• Severe hypoxemia

• Acute hemorrhage

• Ischemic CAD

• Do not use erythropoietin.

43

Glucose Control

• Use arterial or serum blood sugar measurement; capillary blood may not be accurate.

• Treat after two consecutive blood glucose levels

> 180 mg/dL.

• Maintain blood glucose 110-180 mg/dL.

• Monitor every 1-2 hours until stable; then every 4 hours.

44

Do Not Use

• Immunoglobulins

• Selenium

• rhAPC

45

Supportive Therapies

• Renal replacement therapies

• VTE prophylaxis• Sepsis: LMWH

• Septic shock: LMWH + intermittent pneumatic compression

• Stress ulcer prophylaxis (H2 blocker or PPI for patients with severe sepsis factors who have bleeding risk factors

46

Supportive Therapies (cont’d)

• Nutrition (oral or enteral as tolerated within the first 48 hours).

• TPN + enteral for first 7 days for severe sepsis or septic shock.

• Enteral up to 500 cal/day; advance only as tolerated.

47

Ventilator Support

• Target tidal volume 6 mL/kg in patients with sepsis-induced ARDS.

• PEEP to avoid alveolar collapse (higher levels in patients with sepsis-induced moderate or severe ARDS.)

• Recruitment maneuvers in severe refractory hypoxemia.

48

Sedation, Analgesia, and Neuromuscular Blockade

1. Sedation be minimized in ventilated sepsis patients, targeting specific titration endpoints.

2. NMBAs be avoided if possible in the septic patient without ARDS due to the risk of prolonged blockade after d/c’d. If NMBAs must be maintained, TOF monitoring should be used.

3. A short course of NMBA < 48 hours for patients with early sepsis-induced ARDS and a PaO2/FiO2 < 150.

49

For more information:

Dellinger RP, Levy MM, Rhodes A, et al: Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41:580-637.

50

Nursing Implications

• Identify patient at risk• Identify patient who may be developing sepsis• Recognition of subtle changes in condition• Proactive treatment• Emergent resuscitation

51

Nursing’s role in identifying and helping in the treatment of sepsis is more important than ever before.

52

53

Nursing Implications

Methods to minimize host stress response

• Prevent infection• Avoid further tissue damage• Control hyper/hypothermia• Manage pain/anxiety/delirium

54

55

56

57

58

59

60

61

Infection Prevention

• Oral CHG for oropharnygeal decontamination.

• Selective digestive decontamination to prevent VAEs.

62

Nursing Implications

• Source control• Preserve organ function• Prevent complications of nutritional support

prevent obstruction manage diarrhea prevent ileus

63

64

Prognosis: Factors to Consider

• Patient’s underlying health status• Development of organ failure• Prevention of complications• Infecting organism• Shock and low arterial pH during first days

65

Sepsis Mortality

3

710

17 16

20

46

0

5

10

15

20

25

30

35

40

45

50

1

Severity of Disease

Mortality

No SIRS

SIRS2

SIRS3

SIRS4

Sepsis

Severe Sepsis

Shock

Rangel-Frausto, et al., 1995. JAMA 273: 117-2366

Complications of Sepsis and SIRS

• CNS Dysfunction (19%)• ARDS (2-8%)• Liver Failure (12%)• Acute Renal Failure (9-23%)• DIC (8-19%)

67

68

Patients admitted with septic shock to ED• Reduction in mortality: 70% vs. 52%• 5-day reduction in hospital LOS• Reduction in costs: $16,103 vs. $21,985

Schorr AF, Micek ST, Jackson WL, Kollef MH – CCM 2007;35:1257-1262

Implications of SSC Implementation

69